NanoEcho (NANECH) Q3 2024 earnings summary

Executive summary

• Achieved key milestones in Q3 2024, including successful listing on Nasdaq First North Growth Market and preparations for clinical studies.

• Over-subscribed share issue raised 17.0 MSEK, strengthening financial position for continued commercialization efforts.

• Clinical study application approved; recruitment for dose confirmation study initiated.

• Product development completed; system ready for clinical use.

Financial highlights

• Net sales for Q3 and nine months: 0 TSEK (0 TSEK year-over-year), reflecting pre-revenue clinical phase.

• Q3 result after tax: -2,963 TSEK (-2,939 TSEK year-over-year); nine months: -11,637 TSEK (-10,239 TSEK year-over-year).

• Cash flow from operations Q3: -3,681 TSEK (-2,992 TSEK year-over-year); nine months: -13,015 TSEK (-10,078 TSEK year-over-year).

• Cash and cash equivalents at period end: 11,690 TSEK (18,534 TSEK year-over-year).

• Equity at period end: 21,982 TSEK (22,690 TSEK year-over-year); solid equity ratio of 89%.

Outlook and guidance

• Focus remains on clinical validation and regulatory approval, with market launch targeted post-2027.

• Commercialization strategy based on distributor partnerships and recurring revenue from consumables.

• Ongoing evaluation of alternative business models as commercialization approaches.